M B Urowitz
Overview
Explore the profile of M B Urowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
5330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tselios K, Gladman D, Touma Z, Su J, Anderson N, Urowitz M
Lupus
. 2018 Dec;
28(1):114-122.
PMID: 30526328
Background: Disease activity in systemic lupus erythematosus follows three different courses: long quiescent, relapsing remitting and persistently active. However, the patterns of disease course since diagnosis are not known. This...
2.
Jorge A, Melles R, Zhang Y, Lu N, Rai S, Young L, et al.
Arthritis Res Ther
. 2018 Jul;
20(1):133.
PMID: 29976231
Background: Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing. However,...
3.
Tselios K, Gladman D, Harvey P, Su J, Urowitz M
Lupus
. 2018 Apr;
27(9):1415-1423.
PMID: 29665757
Background Severe brady-arrhythmias, requiring a permanent pacemaker (PPM), have been sparsely reported in systemic lupus erythematosus (SLE). The aim of this study was to describe the characteristics of such arrhythmias...
4.
Tanwani J, Tselios K, Gladman D, Su J, Urowitz M
Lupus
. 2018 Apr;
27(8):1296-1302.
PMID: 29642752
Background Lupus myocarditis (LM) is reported in 3-9% of patients with systemic lupus erythematosus (SLE) but limited evidence exists regarding optimal treatment and prognosis. This study aims to describe LM...
5.
Tselios K, Deeb M, Gladman D, Harvey P, Urowitz M
Lupus
. 2017 Oct;
27(4):591-599.
PMID: 28992800
Background Antimalarials (AMs) are widely used in the treatment of connective tissue diseases. Their main side effect is retinal damage, while heart disease has been described in isolated cases. The...
6.
Pakchotanon R, Gladman D, Su J, Urowitz M
Lupus
. 2017 Sep;
27(3):468-474.
PMID: 28857717
Objective The objective of this paper is to identify the relationship between patients with lupus nephritis (LN) who achieve sustained complete renal remission (CR) and renal outcome and survival. Methods...
7.
Deeb M, Tselios K, Gladman D, Su J, Urowitz M
Lupus
. 2017 Aug;
27(3):365-371.
PMID: 28758573
Introduction Shrinking lung syndrome (SLS) is a rare manifestation of systemic lupus erythematosus (SLE), characterized by decreased lung volumes and extra-pulmonary restriction. The aim of this study was to describe...
8.
Chan K, Clarke A, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz M, et al.
Lupus
. 2017 Jun;
27(1):120-123.
PMID: 28595511
Objective There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE,...
9.
Gladman D, Dhillon N, Su J, Urowitz M
Lupus
. 2017 May;
27(1):76-81.
PMID: 28530464
Objective Osteonecrosis is a serious comorbidity in patients with systemic lupus erythematosus. The aims of this study were to describe the prevalence of symptomatic osteonecrosis, determine the pattern of joint...
10.
Aljohani R, Gladman D, Su J, Urowitz M
Lupus
. 2017 Apr;
26(11):1190-1196.
PMID: 28420066
Objective The objective of this study was to compare clinical features, disease activity, and outcome in late-onset versus early-onset systemic lupus erythematosus (SLE) over 5 years of follow up Method...